Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q1 FY26 results · Apr–Jun 2025
Torrent Pharmaceuticals reported revenue from operations of ₹3,178.00 crore (up 11.2% from Q1 FY25) and net profit of ₹548.00 crore (up 19.9% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,178.00 | 2,859.00 | +11.2% | 2,959.00 | +7.4% |
| Other income | (37.00) | 24.00 | Turned loss | (18.00) | Loss widened |
| Total income | 3,141.00 | 2,883.00 | +8.9% | 2,941.00 | +6.8% |
| Profit before tax | 738.00 | 656.00 | +12.5% | 665.00 | +11.0% |
| Net profit for the period | 548.00 | 457.00 | +19.9% | 498.00 | +10.0% |
| EPS, basic (₹) | 16.19 | 13.51 | +19.8% | 14.71 | +10.1% |
| Net margin (%) | 17.2 | 16.0 | 16.8 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,616.00 | 2,438.00 | +7.3% | 2,433.00 | +7.5% |
| Other income | (5.00) | 21.00 | Turned loss | 15.00 | Turned loss |
| Total income | 2,611.00 | 2,459.00 | +6.2% | 2,448.00 | +6.7% |
| Profit before tax | 742.00 | 667.00 | +11.2% | 622.00 | +19.3% |
| Net profit for the period | 551.00 | 469.00 | +17.5% | 474.00 | +16.2% |
| EPS, basic (₹) | 16.28 | 13.86 | +17.5% | 14.00 | +16.3% |
| Net margin (%) | 21.1 | 19.2 | 19.5 |
Consolidated
- Filed with BSE
- 28 Jul 2025, 17:30 IST
- Board meeting
- 28 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jul 2025, 17:30 IST
- Board meeting
- 28 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Audited
- Source
- XBRL filing on BSE